Autopsy report · NCT00349752

Corticosteroid Sparing Effect of Certolizumab in Crohn's Disease

“Recruitment was stopped early due to slow enrolment of this population. With no safety concerns, the study continued normally for subjects already recruited”

The sponsor’s own words in the registry.

Life of this trial

• Registered 5 months before it started.
• Ran for about 2 years 8 months before it stopped.
• 174 participants enrolled.
• Results were posted on the registry 1 year 5 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

UCB Pharma

Sponsor type

Industry

Conditions

Crohn's Disease

Interventions

certolizumab pegol 400 mg; Placebo

Participants

174

Sites

68

Countries

Canada, Germany, United States

Trials that died the same way

• The Effect of Ovamax on Oocyte Quality
  “The study was stopped prematurely due to low recruitment rate” (82% match in meaning)
• Obesity Hypoventilation Syndrome Prevalence Study
  “This study was stopped due to low recruitment.” (81% match in meaning)
• Fondaparinux 1,5 mg for the Prevention of Venous Thromboembolism (VTE) in Medical Patients With Renal Insufficiency
  “study was stopped after enrolment of about 200 patients for slow recruitment” (81% match in meaning)
• Nifedipine or Nifedipine Plus Indomethacin for Treatment of Acute Preterm Labor
  “Study halted due to slow recruitment” (79% match in meaning)
• Exercise to Prevent Aromatase Inhibitor Side Effects in Breast Cancer Patients
  “The study was stopped due to recruitment difficulties” (79% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.